To determine whether the use of nephron-sparing surgery (NSS) for treatment of stage 1 renal cell carcinoma (RCC) changed between 2009 and the end of 2013 in Australia.
Introduction
Based on evidence showing that similar cancer control outcomes are achieved when small tumours of the kidney are treated by nephron-sparing surgery (NSS) as when treated by radical nephrectomy [1] , treatment guidelines for the management of patients with RCC published since the late 2000s have recommended NSS as the preferred standard of care for small tumours (<4 cm, cT1a tumours) [2] [3] [4] . While European guidelines also recommend NSS as the preferred treatment option for tumours up to 7 cm (cT1b), US guidelines suggest that either NSS or radical nephrectomy can be used for these tumours. Both European and US guidelines state that laparoscopic surgical procedures are preferred for radical nephrectomy [3, 4] .
While the benefits of NSS for the patient include reduced risk of cardiovascular disease and chronic kidney disease [5] [6] [7] , other work has suggested it may be associated with a greater complication rate [8] , especially in larger tumours [9] . This, coupled with the greater complexity of NSS, suggests that its adoption could be concentrated to more experienced, highvolume doctors and centres [10] . Research from the USA, however, has suggested this is not the case, with several population-based studies showing that use of NSS for small tumours increased substantially during the 2000s [11] [12] [13] with, for instance, one study reporting that use of NSS for T1a tumours increased from 5% in 1988 to 40% in 2008 [11] , while another reported use increased from 43% in 2004 to 55% in 2009 [14] , the year the AUA published their treatment guidelines recommending this NSS for cT1a tumours. Similarly, population-based studies from Europe have suggested that 50% or more of patients with small renal tumours were treated by NSS in 2010, with for instance, a population-based study from the Netherlands finding that 49% of cT1a tumours were treated by NSS in 2010 [15] , while a study of treatment of T1a tumours in 56 centres in France found that 77% were treated by NSS in 2010 [16] .
In contrast to the patterns found in the USA and Europe, in Australia, the use of NSS for the treatment of small renal tumours was substantially lower during the 2000s. A population-based study examining the treatment of RCC in Australia's most populous state, New South Wales, found that the use of NSS for localized RCC increased from 11% to 23% between 2001 and 2009 [17] . Unfortunately, this paper did not report data for T1a and T1b tumours separately; however, a population-based study from Australia's second most populated state, Victoria, reported that 27% of all T1 tumours and 39% of T1a tumours were treated by NSS in 2009 [18] . This study also found that NSS for T1a tumours was less likely for patients residing in regional (26%) than metropolitan (43%) areas.
Although Australia does not have its own treatment guidelines for RCC, the publication of US and European guidelines since 2009 recommending NSS for small kidney tumours are likely to have influenced clinical practice in Australia. Contemporary estimates are needed to determine whether the use of NSS in the treatment of small renal cell tumours in Australia has increased or whether they still lag behind rates found in Europe and the USA. In the present study, we used population-based data from the Australian state of Victoria to examine how the use of NSS for T1 RCCs changed between 2009 and 2013.
Patients and Methods

Procedure
The population-based Victorian Cancer Registry (VCR) identified all adult cases (age >18 years) of RCC (ICD-O-3 code C649) diagnosed in the three study periods: 1 January For each case, the VCR identified the notifying hospital. Public and private hospitals were approached regarding medical record review of each patient attending their service for treatment. If a hospital refused participation, clinicians involved with the care of that patient, also identified through the VCR, were approached regarding medical record review. Trained data managers attended each participating site to extract relevant data by retrospective review of medical records and pathology reports. If a patient attended multiple treatment sites during their cancer care, treatment details were sought from each site. The study had ethical approval from the Cancer Council Victoria and other institutions as needed.
Data extracted included: mode of presentation; diagnostic and staging investigations; clinical and pathological disease stage; and first-line treatment (e.g. type of surgery and surgical procedure). Comorbidity was assessed using information recorded in the medical record on the Adult Comorbidity Evaluation 27 (ACE-27); a validated comorbidity risk assessment tool developed for patients with cancer. Patients were assigned a comorbidity score of 0-3 (0, none; 1, mild; 2, moderate; and 3, severe). Patients' residential postcodes were used to determine their socio-economic status (SES) using the area-based Index of Relative Socio-Economic Disadvantage (IRSD) developed by the Australian Bureau of Statistics [19] . The IRSD ranks postcodes from most disadvantaged to least disadvantaged. This ranking was collapsed into three levels to reflect the top 33%, middle 33% and bottom 33%. Patient residency and hospital rurality were also categorized using postcode data into 'major city' and 'non-major city' (referred to hereafter as 'metropolitan' and 'regional/rural', respectively) using the Australian Statistical Geography Standard for Remoteness Structure developed by the Australia Bureau of Statistics [20] . Using sample data, the number of RCC cases treated at each hospital in Victoria was determined. Hospital volume was classified into three groups reflecting the treatment of 1-14, 15-29, and ≥30 cases per year. These thresholds were chosen to allow a similar number of cases in each volume group.
Tumour stage was determined from clinical and pathological T stage, nodal and metastatic disease status. Pathological T stage (pT) was categorized according to the American Joint Committee on Cancer (AJCC) staging system where nephrectomy specimens were available for pathological review [21] . Information regarding presence of metastatic disease was not available from pathological staging data for 162 patients. Case notes for all 162 patients were reviewed and metastatic disease was indicated for 100 patients who were assigned an M1 classification. For 47 cases, pT stage was supplemented by AJCC clinical stage information from imaging reports and case notes. The remaining 15 cases did not have any staging information available.
For the current paper we focus on patients with stage 1 tumours classified as T1N0M0 according to the AJCC classification [21] .
Data Analysis
Chi-squared tests were used to examine differences in proportions; ANOVA techniques were used to examine differences in means. Chi-squared tests examined associations between patient residential and treatment location, disease characteristics at diagnosis, and patient characteristics (age, sex, comorbidity levels and SES) and year of study. Chisquared tests also examined the significance of change in the proportion of patients treated by NSS and the proportion treated using laparoscopic surgery between 2009 and 2013, stratifying by patient and treatment centre characteristics. Univariable logistic regression analyses examined the association between patient and treatment centre characteristics and treatment by NSS for T1a and T1b tumours. Multivariable logistic regression examined the association between patient, disease and treatment centre characteristics and treatment by NSS adjusting for other variables in the model.
Results
Responses and Caseloads
In 2009, 577 primary RCC tumours were registered with the VCR. Of these, data were collected on 499 patients, giving a completion rate of 86%. For the period 1 January 2012 to 31 December 2013, 1 380 primary RCC tumours were registered and data were collected on 1 337 patients (response rate: 97%). The proportion of stage 1 tumours was 64% in 2009, 66% in 2012, and 69% in 2013 (P = 0.12).
Characteristics of Patients and Tumours
There were no statistically significant differences in the age, gender, urban/rural residence, and comorbidities of patients with stage 1 tumours in the three survey periods ( Table 1) . SES of patients differed across the three survey years, with more patients in 2009 having a higher SES classification than patients in 2012 or 2013 (P < 0.05). Approximately 60% of tumours were diagnosed incidentally in each survey year (Table 1 ).
In each survey year,~60% of the T1 tumours were T1a tumours and~70% were clear-cell type. The proportion of cases treated in low-volume hospitals reduced over the study period from 30% in 2009 to 17% in 2013 (P < 0.01). This decrease was associated with an increase in the proportion of cases treated at middle-volume hospitals (from 24% to 38%) rather than an increase in the proportion of cases treated at the highest-volume hospitals.
Trends in the Treatment of T1 Tumours
For all T1 tumours and for T1a tumours the proportion of metropolitan and regional/rural patients receiving NSS increased across the survey period ( Fig. 1) . For T1a tumours, the proportion of metropolitan patients receiving NSS increased from 43% in 2009 to 58% in 2012 (P < 0.05), increasing again to 69% in 2013 (P < 0.05). For regional Of metropolitan patients with T1a tumours undergoing NSS, the proportion receiving laparoscopic surgery increased significantly, from 22% in 2009 to 32% in 2012 (P < 0.05), but the change between 2012 and 2013 (40%) was not statistically significant (P = 0.13). The proportion of regional/ rural patients with T1a tumours treated by laparoscopic NSS also increased between 2009 (8%) and 2012 (30%; P < 0.01), but did not change significantly between 2012 and 2013 (28%; P = 0.79).
Univariable and multivariable associations with the use of NSS for T1a tumours are shown in Table 2 . In univariable analyses, patients with more comorbidities (P < 0.05), those residing in regional areas (P < 0.05), those with a lower SES (P < 0.05) and those attending low-volume treatment centres (P < 0.01) were less likely to be treated by NSS (Table 3) ; however, in multivariable analyses that included survey year, only year was significantly related to NSS. There was no significant interaction between year and the demographic factors of age and SES, indicating that the increase in use of NSS over time was consistent across the different demographic groups. Table 3 shows the increase in the use of NSS for T1a tumours within each of the different demographic factors across time. NSS increased in all comorbidity groups, all SES groups and all age groups. In addition, the use of NSS increased for patients treated in public and private hospitals. The use of NSS also increased significantly in hospitals with different RCC volumes.
Trends in the surgical care of T1b tumours are shown in Table 4 . Of those patients undergoing surgery, the use of radical nephrectomy decreased over the study period from 92% in 2009 to 80% in 2013 (P < 0.05), while the use of NSS increased from 8% in 2009 to 20% in 2013 (P < 0.05). The proportion of patients treated by open or laparoscopic NSS or radical nephrectomy in each study year is shown in Table 4 . While there was a significant decrease in the proportion of patients treated by open radical nephrectomy (P < 0.01), the change in the proportion of cases treated by laparoscopic radical nephrectomy or open or laparoscopic NSS was not statistically significant (Table 4) . When any NSS was considered, there was a significant increase in the proportion of patients aged <55 years (P = 0.02), women (P = 0.02) and those with no comorbidities (P = 0.03) undergoing NSS for T1b tumours. While increases in the use of NSS for T1b tumours were found for patients treated in both public and private hospitals and in hospitals with different caseloads, only the increase for patients attending private hospitals was statistically significant (P = 0.05).
Discussion
The present population-based study on the management of T1 renal tumours in Australia found that the use of NSS for T1a tumours increased substantially between 2009 and 2012, with a further increase found between 2012 and 2013. It also found an increase in the use of NSS in the treatment of T1b tumours over this period. Encouragingly, the increase in use of NSS for T1a tumours was seen in all demographic groups, in both public and private hospital systems and in both lowand high-volume hospitals, suggesting that all patients were benefiting from these clinical practice changes. The use of laparoscopic surgery for T1a tumours also increased over the study period, with this increase found for both metropolitan and regional/rural patients. Taken together, these changes suggest that, between 2009 and 2013, clinical practice for the treatment of small renal tumours in Australia has increasingly conformed to international guidelines [2] [3] [4] , with patients treated by less clinically invasive surgery. The study also suggests that, at least in the Australian state of Victoria, specific population groups were not missing out on the benefits of these clinical practice changes.
Sun et al. [11] suggested that, during the 2000s, the treatment of small renal tumours underwent a paradigm shift, with NSS becoming the standard of care. The present study shows that, in Australia, this paradigm shift occurred after 2009, with NSS becoming the most commonly used treatment for T1a tumours. We found that the proportion of patients with T1a tumours treated by NSS increased by 77% between 2009 and 2013, and that 62% of T1a tumours were treated by this surgical procedure in 2013. With this change, surgical management of T1a tumours in the Australian state of Victoria is now similar to practice patterns found in the Netherlands [15] , Sweden [22] and the UK [23] .
The evidence regarding the impact of the publication of clinical guidelines on practice is mixed, with some studies finding a positive impact [15, 24, 25] , some showing only a small impact [26, 27] , and others showing no impact [28] . As we do not have data regarding the surgical management of small RCC tumours prior to 2009, we do not know whether use of NSS to treat T1a tumours was increasing during the 2000s, suggesting the increase we found between 2009 and 2013 was simply a continuation of this trend; however, Patel et al. [17] showed that use of NSS for all RCC tumours was relatively stable between 2005 and 2008 at 20% in the Australian state of New South Wales. While not conclusive, this could suggest the increase in NSS found in the present study was in response to the publication of the international guidelines recommending use of NSS for small renal tumours.
Similarly to other studies [10, 12] , the present study showed that receiving NSS for the treatment of T1a tumours was associated with some demographic and treatment centre characteristics. In univariable analyses, older patients, those with more comorbidities, those with a lower SES, regional patients and those treated at low-volume treatment centres were less likely to be treated by NSS; however, in multivariable analyses that included study year, only patients' SES remained significantly associated with NSS, with high SES patients more likely to receive NSS than patients from NSS, nephron-sparing surgery; OR, odds ratio.
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© 2017 The Authors BJU International © 2017 BJU International the lowest SES group. As there was no significant interaction between year and SES, the present study suggests that, although use of NSS for patients in low SES groups with T1a tumours increased between 2009 and 2013, this increase was not sufficient to ameliorate differences in the surgical approach used for patients with high and low SES.
Over the period of the present study, the proportion of patients treated in low-volume hospitals decreased, while the proportion treated in middle-volume hospitals increased. As several studies, including ours in univariable analyses, have shown a positive association between higher hospital renal cancer volumes and likelihood of NSS [10, 17, 22] , this change is encouraging; however, unlike a recent European study that found no change in the use of NSS for T1 tumours in lowvolume hospitals [29] , the present study found an increasing trend towards NSS for small renal tumours even in lowvolume hospitals. As our study used slightly different definitions for low-volume hospitals, we repeated our analyses using the same volume definitions as those used in the European study [29] , and found the same pattern of results as those presented in this paper. The increase in the use of NSS in low-, middle-and high-volume hospitals over the study period shows that change in surgical management of T1a renal tumours need not be restricted to only high-volume treatment centres. As simulation training has been found to promote skills and technique in different urological surgical techniques [30] , encouraging clinicians to undertake simulation training in relation to NSS techniques may help to further increase the use of NSS for small renal tumours.
Our multivariable analyses, which adjusted for study year and patient characteristics, did not find a significant association between hospital volume and NSS for T1a tumours. Indeed in these analyses, study year was the only variable significantly associated with NSS. Other studies have also failed to find a significant association between hospital volume and NSS for small renal tumours in multivariable analyses that adjust for patient factors, diagnosis year, surgeon volume and/or hospital type (e.g. community, university) [31] . It was not possible to identify individual surgeon volume in the present study. Because this factor has been found to be an important determinant of surgical procedures for small renal tumours [31] , its omission may have influenced the results from our multivariable analyses. Future research is required to investigate the relative role of surgeon and hospital characteristics in the use of NSS for small renal tumours.
A study from the Netherlands reported that rates of NSS were slightly lower at university hospitals than at other hospitals because university hospitals are more likely to use ablation procedures for the treatment of small tumours [15] . As we did not examine the use of these minimally invasive procedures, we cannot determine whether the lower rates of NSS in high-volume hospitals in 2013 were attributable to greater use of other treatment procedures at these centres; however, we did not find a change in the proportion of cases not treated by surgery at high-volume hospitals over the study period (data not shown). Future studies need to include the use of ablation in the treatment of small renal tumours and determine whether use of this procedure differs by characteristics of the treatment centre and/or patient.
Despite guidelines suggesting that NSS should be considered when treating T1b tumours, the present study showed that, of the patients undergoing surgery, the vast majority were treated by radical nephrectomy (80%) in 2013. While there was some increase in the use of NSS in this group, the present data suggest that only a small minority of T1b tumours receiving surgery for their RCC were treated by NSS in Australia. Although we did find that the use of NSS for T1b tumours increased in the different demographic and hospital groups, few differences were statistically significant, possibly because of the small number of cases with T1b tumours in our dataset. Larger studies are needed to determine the significance of changes in the surgical management of T1b tumours for different sociodemographic groups. While use of open radical nephrectomy decreased over the study period, there was little change in the proportion of patients with T1b tumours treated by laparoscopic radical nephrectomy. This suggests that the decrease in use of open radical nephrectomy was attributable to an increase in use of NSS rather than clinicians shifting to a laparoscopic procedure for radical nephrectomy. While others have suggested that greater use of laparoscopic surgical procedures may be hindering the uptake of NSS for T1b tumours [14] , our results suggest that this may not be the case in Australia. Our rates of NSS for T1b tumours in 2013 were similar to levels found in the USA in 2009 (18%), but lower than levels seen in the Netherlands (28%) in 2013 [15] . The present study suggests that, in Australia, T1b tumours are still largely treated by radical nephrectomy.
There is some suggestion that the diagnosis of asymptomatic renal tumours has increased because of the greater proportion of cases detected incidentally [32] . Although we found a decrease in the proportion of symptomatic cases between 2009 and 2013, this change may have been an artefact of the data collection process as there was a greater proportion of cases with missing data on this variable in 2012-2013 than in 2009. As the proportion of T1a tumours did not change over the study period, our data suggest that there has not been a A strength of the present study is its population-based approach, which enabled us to gather treatment data on all patients diagnosed with RCC in Victoria. This approach meant that our study was able to assess community-wide practice patterns rather than assessing the treatment delivered at a specific treatment centre. Rather than asking clinicians to report on the care they delivered to specific patients, we assessed treatment through review of medical records. While this meant we could gather unbiased information on the treatment patients actually received, it relies on good documentation of all procedures received in the medical records. Procedures that were not documented in the medical record could not be gathered in the present study. As this study did not involve clinicians or patients, we do not know what role clinician experience or patient preferences have played in determining the treatment received. We did not collect data on the management of RCCs diagnosed in 2010 and 2011 and were unable to determine whether the increase in the use of NSS for T1a tumours commenced from 2009 or slightly later. Administrative data sets, that can stratify cases by their cT stage, would enable long-term year-on-year change in use of NSS for small renal tumours to be examined. As oncocytomas may be indistinguishable from renal cancers radiologically [33] , it is possible that some cT1a tumours among those that were not treated by surgery were oncocytomas. Finally, while we attempted to examine factors associated with use of NSS for T1b tumours, the small number of cases with tumours this size meant our analyses were limited in scope and statistical power.
Despite these limitations, we believe the present study has provided important new information regarding the treatment of T1 renal tumours in Australia. The study has shown that the treatment of small renal tumours in Australia has undergone a substantial change in a relatively short period, with NSS now the standard of care for T1a tumours. Our data suggest that although the treatment of small renal tumours is increasingly in line with international standards, this is not the case for the treatment of larger T1 tumours. The slow adoption of NSS in the treatment of T1b tumours warrants further investigation to identify barriers to its use.
